The need for new antibiotics to combat multi-drug resistant bacteria has led U.S. chemists to the first synthesis of a potentially valuable antibiotic.
Daniel Kahne and colleagues at Harvard University report the first total synthesis of the antibiotic moenomycin -- a drug that has been sidelined from clinical use for 40 years.
Moenomycin is a broad-spectrum antibiotic with strong antibacterial activity against a large group of bacteria that cause pneumonia, urinary tract infections, gastritis, stomach ulcers, food poisoning and other disorders. Moenomycin also kills bacteria in an unusual way -- it binds directly to enzymes that bacteria need to form a cell wall.
Although used as a growth promoter in animals, moenomycin has never been developed for medical use in humans because it is poorly absorbed into the body. Kahne says discovery of a method to synthesize moenomycin is important because it will allow scientists to better understand the antibiotic and make variants of the natural antibiotic that may be suitable for medical use.
The research appeared in the Nov. 15 issue of the Journal of the American Chemical Society.
Copyright 2006 by United Press International
Related stories:
Atomic structure of the mammalian 'fatty acid factory' determined
Mammalian fatty acid synthase is one of the most complex molecular synthetic machines in human cells. It is also a promising target for the development of anti-cancer and anti-obesity drugs and the treatment of metabolic disorders. Now researchers at ETH Zurich have determined the atomic structure of a mammalian fatty acid synthase. Their results have just been published in
Science magazine.
'Superbug' breast infections controllable in nursing mothers, researchers find
Many nursing mothers who have been hospitalized for breast abscesses are afflicted with the "superbug" methicillin-resistant
Staphylococcus aureus, or MRSA, but according to new research by UT Southwestern Medical Center physicians, conservative treatment can deal with the problem.
Stick with simple antibiotics for pneumonia to avoid super bugs, says researcher
Australian hospitals should avoid prescribing expensive broad-spectrum antibiotics for pneumonia to avoid the development of more drug-resistant super bugs, according to a University of Melbourne study.
Rapid test for pathogens developed by K-State researchers
Dangerous disease often spreads faster than it takes to diagnose it in the lab. To remedy that, researchers at Kansas State University have developed a test to bring that time from days down to hours.
Scientists uncover molecule that keeps pathogens like salmonella in check
Scientists at UT Southwestern Medical Center have found a potential new way to stop the bacteria that cause gastroenteritis, tularemia and severe diarrhea from making people sick.
Study on salmonella self-destruction
ETH Zurich biologists, led by Professors Martin Ackermann and Wolf-Dietrich Hardt, in collaboration with Michael Doebeli of the University of British Colombia in Vancouver (CN), have been able to describe how random molecular processes during cell division allow some cells to engage in a self-destructive act to generate a greater common good, thereby improving the situation of the surviving siblings.
Silver is the key to reducing pneumonia associated with breathing tubes
People have long prized silver as a precious metal. Now, silver-coated endotracheal tubes are giving critically ill patients another reason to value the lustrous metal. In a study published in the Aug. 20, 2008 issue of the
Journal of the American Medical Association, researchers at Washington University School of Medicine in St. Louis and the NASCENT Investigation Group, report that the silver-coated tubes led to a 36 percent reduction of ventilator-associated pneumonia (VAP).
Rifamycin antibiotics attack tuberculosis bacteria with walls, not signals
(PhysOrg.com) -- Amid concerns about the rising number of new tuberculosis cases worldwide, researchers led by Rockefeller University’s Seth A. Darst have reexamined and disproved a theory that describes how a potent class of antibiotics kills a deadly form of bacteria. The findings, which will appear in this week’s online issue of the
Proceedings of the National Academy of Sciences, not only bring scientists closer to understanding how these antibiotics work but also how the bacteria become resistant to their effects.